Skip to content
AI IntelligenceMar 14, 2026Secondary Market
Article

ARWR

Arrowhead Pharmaceuticals (ARWR) posted first fiscal quarter 2026 revenue of $264 million. A key milestone was the approval of REDEMPLO, marking a commercial shift for the company and increasing its focus on therapy commercialization.

Data Cube AI EditorialSource: Yahoo Finance
01

Source Brief

Arrowhead Pharmaceuticals (ARWR) posted first fiscal quarter 2026 revenue of $264 million. A key milestone was the approval of REDEMPLO, marking a commercial shift for the company and increasing its focus on therapy commercialization.